https://halberdcorporation.com/halberd-moves-forward/2020-07-17T12:20:34-04:00https://halberdcorporation.com/halberd-announces-agreement-to-retire-192000000-outstanding-common-shares/2020-04-06T14:24:14-04:00https://halberdcorporation.com/premier-biomedical-halberd-and-gold-river-agree-to-work-jointly-to-develop-premiers-patented-extracorporeal-technology-on-covid-19-treatment-and-proprietary-anti-addiction-patchtm/2020-04-08T17:24:15-04:00https://halberdcorporation.com/halberd-designated-pink-current-information-by-otc-and-continues-technology-progress/2020-06-21T00:55:39-04:00https://halberdcorporation.com/halberd-corporation-appoints-dr-patricio-reyes-to-scientific-advisory-board/2020-06-21T19:04:50-04:00https://halberdcorporation.com/nfl-retired-players-associations-chief-medical-officer-joins-halberd-corporation-to-lead-covid-19-efforts/2020-06-21T20:27:29-04:00https://halberdcorporation.com/halberd-method-for-treating-and-curing-the-covid-19-infection-explained/2020-06-28T19:55:51-04:00https://halberdcorporation.com/halberd-establishes-uk-subsidiary/2020-07-01T10:06:25-04:00https://halberdcorporation.com/covid-19-cytokine-storm-coronavirus-deadliest-stage-halberds-us-patent-pending-treatment-now-explained/2020-07-06T19:47:51-04:00https://halberdcorporation.com/halberd-corp-update-july-13-2020-addresses-certain-issues/2020-07-12T21:15:03-04:00https://halberdcorporation.com/halberd-advances-the-treatment-of-covid-19-utilizing-laser-technology/2020-07-21T11:29:21-04:00https://halberdcorporation.com/halberd-corporation-cto-dr-patricio-reyes-presents-information-at-virtual-event-on-covid-19s-effects-on-neurological-functions/2020-07-30T12:19:33-04:00https://halberdcorporation.com/retired-nfl-great-carl-eller-joins-halberd-corporation/2020-07-30T17:30:57-04:00https://halberdcorporation.com/halberd-corporation-secures-2-million-for-covid-19-research/2020-08-04T08:00:29-04:00https://halberdcorporation.com/halberd-corporation-adds-dr-abdon-nanhay-to-scientific-advisory-board/2020-08-10T08:00:04-04:00https://halberdcorporation.com/halberd-corporation-ceo-answers-shareholders-questions-regarding-covid-19-treatment/2020-08-18T08:00:11-04:00https://halberdcorporation.com/halberd-corporation-selects-university-research-partner/2020-08-27T08:00:21-04:00https://halberdcorporation.com/halberd-selects-arizona-state-university-asu-to-develop-its-patented-covid-19-treatments/2020-08-31T08:00:31-04:00https://halberdcorporation.com/why-halberd-corporation-selected-asu-and-where-they-stand-among-other-universities/2020-09-02T08:00:19-04:00https://halberdcorporation.com/moneytv-with-donald-baillargeon/2020-09-03T14:47:01-04:00https://halberdcorporation.com/halberd-corporation-research-on-covid-19-treatment-development-begins-at-asu/2020-09-08T11:19:17-04:00https://halberdcorporation.com/halberd-corporation-outlines-multi-phase-1-4-m-covid-19-program-in-partnership-with-asu/2020-09-13T20:36:48-04:00https://halberdcorporation.com/asu2/2020-09-17T08:26:31-04:00https://halberdcorporation.com/arizona-state-university-halberd-corp-covid-19-research-program-progress-successful-covid-spike-protein-disease-antigen-re-creation/2020-09-20T20:34:28-04:00https://halberdcorporation.com/arizona-state-university-halberd-corp-covid-19-rd-program-rapid-diagnostic-test-treatment/2020-09-23T20:35:03-04:00https://halberdcorporation.com/arizona-state-university-halberd-pursue-nasal-spray-as-covid-19-preventative-treatment-based-on-childrens-natural-immunity/2020-09-27T19:42:54-04:00https://halberdcorporation.com/halberd-covid-19-preventative-nasal-spray-provisional-patent-application-filed/2020-09-30T20:26:49-04:00https://halberdcorporation.com/halberd-corporation-ceo-update-letter-october-2020/2020-10-07T19:53:21-04:00https://halberdcorporation.com/arizona-state-university-halberd-develop-antibody-against-covid-19/2020-10-12T20:32:43-04:00https://halberdcorporation.com/asu-halberd-initiate-patent-application-for-new-engineered-class-covid-19-antibody/2020-10-19T12:43:39-04:00https://halberdcorporation.com/icymi-halberd-corporation-discusses-the-development-of-new-class-of-covid-19-antibody-with-the-stock-day-podcast/2020-10-25T21:54:06-04:00https://halberdcorporation.com/halberd-corp-retains-prestigious-patent-law-firm-on-covid-19-related-and-other-disease-technologies/2020-10-26T18:49:33-04:00https://halberdcorporation.com/halberd-corp-development-efforts-transcend-covid-19-prevention-diagnostics-therapeutics/2020-10-28T20:28:05-04:00https://halberdcorporation.com/halberd-corp-ceo-interviewed-on-money-tv/2020-11-01T21:04:15-05:00https://halberdcorporation.com/halberd-corp-develops-second-covid-19-antibody-for-enhanced-nasal-spray-and-doubles-performance-of-new-class-of-antibody/2020-11-04T20:08:10-05:00https://halberdcorporation.com/halberd-corporation-files-for-patent-protection-on-enhanced-nasal-spray-to-prevent-covid-19/2020-11-08T20:54:51-05:00https://halberdcorporation.com/halberd-corporation-reveals-patent-pending-fluorescent-antibodys-wide-role-in-covid-19-detection-treatment/2020-11-11T20:25:36-05:00https://halberdcorporation.com/halberd-corp-ceo-interviewed-on-money-tv-discusses-new-fluorescent-covid-19-antibody/2020-11-15T17:29:50-05:00https://halberdcorporation.com/halberd-corporation-files-for-patent-protection-on-covid-19-extracorporeal-treatment-variation/2020-11-18T19:10:48-05:00https://halberdcorporation.com/halberd-corp-ceo-interviewed-on-money-tv-discusses-2020-accomplishments-and-plans/2020-11-24T20:59:01-05:00https://halberdcorporation.com/halberd-corporation-advisory-board-reorganization-announced/2020-11-30T19:45:04-05:00https://halberdcorporation.com/halberd-corporations-covid-19-technology-recognized-by-momentum-observer/2020-12-01T19:46:42-05:00https://halberdcorporation.com/halberd-corp-research-yields-promising-sars-cov-2-antibody-in-laboratory-testing/2020-12-06T16:39:08-05:00https://halberdcorporation.com/halberd-corporation-discusses-positive-antibody-test-results-against-covid-19-with-the-stock-day-podcast/2020-12-09T21:39:40-05:00https://halberdcorporation.com/halberd-corp-research-yields-potent-sars-cov-2-antibody/2020-12-13T17:40:49-05:00https://halberdcorporation.com/halberd-corporation-pursues-extracorporeal-radio-frequency-treatment-against-covid-19/2020-12-16T20:11:40-05:00https://halberdcorporation.com/halberd-corporation-produces-a-second-monoclonal-antibody-against-covid-19-spike-protein/2020-12-22T21:04:30-05:00https://halberdcorporation.com/halberd-corporation-2020-year-end-ceo-letter/2021-01-03T19:11:25-05:00https://halberdcorporation.com/halberd-corporations-covid-19-efforts-recognized-in-wall-street-pr-news-article/2021-01-11T19:57:47-05:00https://halberdcorporation.com/halberd-corp-develops-medication-to-boost-immune-system-against-sars-cov-2-covid-19/2021-01-13T18:47:16-05:00https://halberdcorporation.com/halberd-corporation-discusses-qualitative-quantitative-diagnostic-methodology-for-detecting-covid-19-antibodies-and-antigens-with-the-stock-day-podcast/2021-01-28T08:45:25-05:00https://halberdcorporation.com/halberd-corporations-ceo-interviewed-on-the-stock-day-podcast-and-on-moneytv/2021-01-31T19:36:34-05:00https://halberdcorporation.com/halberd-collaborates-with-greenbioaz-inc-for-the-development-of-its-patent-pending-radio-frequency-technology-to-eliminate-disease-pathogens/2021-02-15T21:23:39-05:00https://halberdcorporation.com/halberds-2nd-proprietary-antibody-against-sars-cov-2-spike-protein-demonstrates-neutralizing-affinity-20-times-greater/2021-03-01T20:05:18-05:00https://halberdcorporation.com/halberd-corporations-ceo-interviewed-on-the-stock-day-podcast-focus-on-halberds-new-20x-affinity-neutralizing-sars-cov-2-antibody/2021-03-08T20:35:16-05:00https://halberdcorporation.com/halberd-corporation-files-vita-shield-maxtm-trademark-for-immunity-boosting-nutraceutical/2021-03-10T19:37:28-05:00https://halberdcorporation.com/halberd-corporation-starts-vita-shield-maxtm-immunity-boosting-nutraceutical-production/2021-03-15T18:53:11-04:00https://halberdcorporation.com/halberd-corporation-files-international-patent-cooperation-treaty-pct-application-covering-extracorporeal-treatment-of-covid-19-and-other-medical-maladies/2021-03-17T21:09:58-04:00https://halberdcorporation.com/halberd-corporation-completes-compilation-of-medical-articles-in-support-of-nutraceuticals-in-their-vita-shield-maxtm-immune-booster/2021-09-28T10:28:40-04:00https://halberdcorporation.com/halberd-corporations-scientific-breakthrough-conjugating-metallic-particles-to-sars-cov-2-and-e-coli-antigens/2021-03-29T20:24:19-04:00https://halberdcorporation.com/halberd-corporation-ceo-letter/2021-04-05T20:46:11-04:00https://halberdcorporation.com/halberd-corporation-files-international-patent-cooperation-treaty-pct-application-on-covid-19-inflammatory-cytokine-storm-treatment/2021-04-11T20:02:28-04:00https://halberdcorporation.com/halberd-corporation-moves-radio-frequency-rf-disease-elimination-effort-forward-with-the-addition-of-youngstown-state-university-ysu-and-dr-william-g-sturrus/2021-04-18T21:39:58-04:00https://halberdcorporation.com/halberd-corporation-files-international-patent-cooperation-treaty-pct-application-on-treating-and-curing-covid-19-infection-utilizing-a-laser/2021-04-25T23:01:11-04:00https://halberdcorporation.com/halberd-corporation-appoints-new-chief-technical-officer-to-optimize-upcoming-experiments-on-radio-frequency-and-laser-eradication-of-disease/2021-05-04T07:46:18-04:00https://halberdcorporation.com/halberd-corp-designated-as-a-breakout-stock-to-watch-in-investor-publications/2021-05-09T20:41:34-04:00https://halberdcorporation.com/halberd-corporation-begins-testing-of-patented-process-for-laser-eradication-of-disease/2021-05-12T20:19:30-04:00https://halberdcorporation.com/halberd-corporation-reports-successful-conjugation-of-metallic-particles-sars-cov-2-proprietary-monoclonal-antibody/2021-05-17T11:12:47-04:00https://halberdcorporation.com/marketwatch-features-halberd-corporation-with-prominent-pharmaceutical-companies-on-new-treatments-for-covid-19/2021-05-18T22:02:25-04:00https://halberdcorporation.com/halberd-corporation-successfully-conjugates-metallic-particles-and-e-coli-antibody/2021-05-24T21:12:58-04:00https://halberdcorporation.com/halberd-corp-files-provisional-patent-application-complementing-patented-extracorporeal-radio-frequency-laser-projects/2021-05-30T12:12:26-04:00https://halberdcorporation.com/halberd-corporation-creates-two-new-and-stronger-sars-cov-2-neutralizing-antibodies/2021-06-06T20:44:05-04:00https://halberdcorporation.com/halberd-corporation-undertakes-process-toward-the-elimination-of-alzheimers-disease/2021-06-08T21:47:47-04:00https://halberdcorporation.com/halberd-corporation-successfully-conjugates-metallic-particles-and-antibodies-against-alzheimers-disease-associated-antigens/2021-06-15T21:04:24-04:00https://halberdcorporation.com/halberd-corporations-proprietary-technology-for-alzheimers-disease-enters-stage-4-of-7-stage-process/2021-06-20T21:56:56-04:00https://halberdcorporation.com/halberd-corp-discovers-a-proprietary-disease-causing-antigen-removal-process/2021-06-29T23:00:53-04:00https://halberdcorporation.com/halberd-corporation-ceo-letter-2/2021-07-05T22:28:30-04:00https://halberdcorporation.com/halberd-corp-advances-the-elimination-of-antigens-present-in-alzheimers-disease-ptsd-chronic-traumatic-encephalopathy/2021-07-21T19:48:45-04:00https://halberdcorporation.com/halberd-corporation-successfully-establishes-disease-eradication-proof-of-concept-never-before-accomplished/2021-07-27T17:35:26-04:00https://halberdcorporation.com/halberd-corporations-vita-shield-maxtm-immunity-support-product-shipped/2021-08-08T15:07:13-04:00https://halberdcorporation.com/halberd-corporation-adds-blood-borne-disease-treatment-capability-with-addition-of-noted-nephrologist/2021-08-10T21:46:53-04:00https://halberdcorporation.com/halberds-disease-elimination-technology-rd-at-youngstown-state-university-ysu-draws-attention-of-cbs-affiliate-wkbn/2021-08-15T14:11:44-04:00https://halberdcorporation.com/halberd-corporations-vita-shield-maxtm-available-buy-now/2021-09-28T10:26:44-04:00https://halberdcorporation.com/halberd-files-provisional-patent-application-furthering-efforts-on-alzheimers-disease/2021-08-22T21:05:51-04:00https://halberdcorporation.com/halberd-receives-patent-for-treatment-of-cockayne-syndrome-may-provide-pathway-to-slow-aging/2021-08-24T20:42:26-04:00https://halberdcorporation.com/halberd-corporation-alzheimers-disease-treatment-tests-yield-outstanding-results/2021-08-29T20:56:56-04:00https://halberdcorporation.com/halberd-corporation-appoints-anthony-mirabelli-vice-president-mergers-acquisitions/2021-09-07T20:16:32-04:00https://halberdcorporation.com/halberds-treatment-eradicates-primary-building-block-of-alzheimers-disease/2021-09-12T21:20:30-04:00https://halberdcorporation.com/halberd-and-heliosdx-of-rushnet-enter-scientific-collaboration-agreement/2021-09-21T19:05:47-04:00https://halberdcorporation.com/halberds-vitashieldmaxtm-immunity-support-product-available-on-amazon/2021-10-04T20:45:12-04:00https://halberdcorporation.com/halberd-corporation-ceo-letter-3/2021-10-04T21:24:09-04:00https://halberdcorporation.com/halberd-and-gtx-corp-sign-scientific-collaboration-and-reseller-agreement/2021-10-11T21:52:59-04:00https://halberdcorporation.com/alpha1/2021-10-19T20:41:18-04:00https://halberdcorporation.com/halberds-ptsd-alzheimers-rd-reveals-link-to-potential-obesity-cure/2021-10-19T21:30:49-04:00https://halberdcorporation.com/interleukin6/2021-10-19T20:31:40-04:00https://halberdcorporation.com/nanoparticles/2021-10-19T20:34:25-04:00https://halberdcorporation.com/tnfalpha/2021-10-19T20:43:06-04:00https://halberdcorporation.com/interleukin-6-induces-impairment-in-human-subcutaneous-adipogenesis-in-obesity-associated-insulin-resistance/2021-10-19T20:51:31-04:00https://halberdcorporation.com/halberd-files-provisional-patent-on-breakthrough-obesity-treatment/2021-10-24T19:32:33-04:00https://halberdcorporation.com/halberd-successfully-eradicates-il-6-a-critical-factor-in-ptsd-cte-alzheimers-disease/2021-10-31T17:47:07-04:00https://halberdcorporation.com/halberd-files-additional-extracorporeal-patent-application-treatment-of-covid-19-by-exposure-to-tuned-radio-frequency-waves/2021-11-07T19:56:42-05:00https://halberdcorporation.com/halberd-successfully-eradicates-tnf-%ce%b1-a-major-contributing-factor-to-alzheimers-disease/2021-11-21T20:32:25-05:00https://halberdcorporation.com/halberd-follow-up-verification-tests-prove-100-eradication-of-tnf-alpha-a-major-contributing-factor-to-alzheimers-disease-and-ptsd-cte/2021-12-05T19:03:46-05:00https://halberdcorporation.com/halberd-successfully-eradicates-interluekien-1-in-its-continued-progress-toward-eliminating-neurodegenerative-diseases/2021-12-12T18:23:45-05:00https://halberdcorporation.com/halberd-eradicates-another-inflammatory-cytokine-interleukin-12-in-its-continuing-effort-to-eliminate-neurodegenerative-diseases/2021-12-14T20:33:30-05:00https://halberdcorporation.com/halberd-moves-closer-to-proving-its-patented-technologies-eliminate-contributors-to-neurodegenerative-diseases/2021-12-19T18:05:14-05:00https://halberdcorporation.com/halberd-corporation-now-an-official-us-government-contactor/2022-01-04T20:14:00-05:00https://halberdcorporation.com/halberd-ceo-letter-2021-year-end-2022-outlook/2022-01-24T18:26:05-05:00https://halberdcorporation.com/halberd-achieves-landmark-selective-elimination-of-tau-from-an-antigen-mixture/2022-01-31T18:55:40-05:00https://halberdcorporation.com/halberd-eliminates-100-of-tau-protein-from-csf-the-9th-of-10-target-neurodegenerative-disease-antigens/2022-02-07T18:58:11-05:00https://halberdcorporation.com/halberd-medical-breakthrough-for-the-treatment-of-neurodegenerative-diseases-affecting-36-million-americans-annually/2022-02-21T18:59:51-05:00https://halberdcorporation.com/halberds-covid-19-antibody-is-the-only-one-in-competitive-tests-to-bind-to-omicron-variant/2022-03-01T10:07:25-05:00https://halberdcorporation.com/halberd-expands-its-technical-expertise-with-the-addition-of-microbiology-professor/2022-03-07T23:31:23-05:00https://halberdcorporation.com/infectious-disease-specialist-will-guide-halberds-extracorporeal-elimination-of-disease-antigens-in-animals-and-then-humans/2022-03-15T22:01:14-04:00https://halberdcorporation.com/halberd-corporation-brief-overview/2022-03-25T09:57:20-04:00https://halberdcorporation.com/halberd-continues-in-vitro-successes-with-elimination-of-protein-linked-to-depression/2022-04-05T20:32:09-04:00https://halberdcorporation.com/halberd-entering-the-medical-metaversetm/2022-04-10T18:42:06-04:00https://halberdcorporation.com/halberd-eliminates-e-coli-in-20-minutes-vs-7-10-days-with-conventional-antibiotics/2022-04-17T19:16:30-04:00https://halberdcorporation.com/halberd-ceo-letter/2022-04-24T18:20:33-04:00https://halberdcorporation.com/dr-gregg-sturrus-tedx-talkr-features-halberds-extracorporeal-treatment-of-neurodegenerative-diseases/2022-04-27T16:28:20-04:00https://halberdcorporation.com/halberd-submits-audited-financials-files-form-10-as-first-step-to-up-list-to-otcqb/2022-05-11T18:58:14-04:00https://halberdcorporation.com/halberd-engages-professional-firm-to-proceed-with-fda-filings/2022-05-17T18:30:32-04:00https://halberdcorporation.com/halberd-successfully-eliminates-excess-levels-of-inflammatory-cytokines/2022-05-24T05:22:45-04:00https://halberdcorporation.com/halberd-corp-mississippi-state-university-discuss-animal-testing-as-prelude-to-fda-certification/2022-06-07T21:21:57-04:00https://halberdcorporation.com/halberd-creates-subsidiary-to-apply-its-patented-technology-to-treat-cancer/2022-06-21T05:23:46-04:00https://halberdcorporation.com/halberd-corporation-update-ceo-letter-and-2022-expectations/2022-07-11T19:19:34-04:00https://halberdcorporation.com/halberds-antibody-effective-against-all-4-sars-cov-2-mutations-including-omicron/2022-07-13T20:33:40-04:00https://halberdcorporation.com/halberd-corp-launches-halberd-cancer-therapeutics-ltd-wholly-owned-subsidiary/2022-07-19T20:21:05-04:00https://halberdcorporation.com/nfl-retired-players-association-endorses-halberd-brain-injury-treatment-technology/2022-08-03T21:28:03-04:00https://halberdcorporation.com/halberd-demonstrates-precise-control-of-key-cancer-related-t-cell-protein/2022-08-22T20:05:56-04:00https://halberdcorporation.com/halberd-enters-strategic-alliance-for-longevity-alzheimers-disease-and-cancer-early-detection-prevention-and-treatment/2022-09-26T21:24:04-04:00https://halberdcorporation.com/halberd-progresses-from-eliminating-top-brain-disease-antigens-from-csf-to-eradication-of-interleukin-6-from-human-blood-serum/2022-10-11T20:09:20-04:00https://halberdcorporation.com/halberd-laser-therapy-eliminates-over-90-of-multiple-bacterial-cells-in-minutes/2022-10-17T20:12:29-04:00https://halberdcorporation.com/halberd-signs-development-and-marketing-agreement-for-medications-nutraceuticals/2022-11-14T10:09:21-05:00https://halberdcorporation.com/halberd-corporation-achieves-groundbreaking-pre-clinical-endpoint-by-eradicating-cancer-disease-antigen-linked-to-breast-cancer/2022-11-17T05:15:05-05:00https://halberdcorporation.com/halberd-team-produces-peer-reviewed-article-on-antibody-against-covid-19-omicron-variant/2022-11-30T19:22:58-05:00https://halberdcorporation.com/the-street-podcast-features-halberds-groundbreaking-cancer-treatment-approach-listen-now/2022-12-04T16:15:09-05:00https://halberdcorporation.com/halberd-receives-several-strains-of-antibiotic-resistant-bacteria-from-cdc-to-test-laser-eradication/2022-12-05T19:18:54-05:00https://halberdcorporation.com/halberd-corporation-2022-year-end-ceo-letter-and-2023-goals/2023-01-02T20:07:25-05:00https://halberdcorporation.com/halberd-agrees-to-animal-testing-at-mississippi-state-university/2023-01-23T17:04:28-05:00https://halberdcorporation.com/halberd-demonstrates-eradication-of-cdc-provided-antibiotic-resistant-bacteria/2023-02-08T04:58:45-05:00https://halberdcorporation.com/halberd-corporation-announces-breakthrough-in-candida-auris-treatment/2023-02-12T19:53:01-05:00https://halberdcorporation.com/halberd-demonstrates-simultaneous-eradication-of-multiple-strains-of-cdc-provided-antibiotic-resistant-bacteria/2023-02-21T05:34:56-05:00https://halberdcorporation.com/halberd-centers-for-disease-control-to-meet-regarding-eradication-of-antibiotic-resistant-pathogens/2023-03-14T05:42:44-04:00https://halberdcorporation.com/halberd-eradicates-all-strains-of-antibiotic-resistant-e-coli-provided-by-the-cdc-at-youngstown-state-university/2023-03-21T18:30:21-04:00https://halberdcorporation.com/halberd-and-mississippi-state-university-msu-sign-agreement-to-conduct-pre-clinical-model-tests-of-nasal-spray-to-block-negative-effects-of-head-trauma/2023-03-29T19:43:38-04:00https://halberdcorporation.com/halberds-successful-meeting-with-cdc-leads-to-expanded-testing-of-antibiotic-resistant-pathogens/2023-04-03T05:07:20-04:00https://halberdcorporation.com/halberd-begins-preclinical-testing-at-mississippi-state-university-msu/2023-04-11T08:01:10-04:00https://halberdcorporation.com/halberd-research-featured-on-youngstown-oh-cbs-affiliate-news-station-segment/2023-04-16T18:54:51-04:00https://halberdcorporation.com/icymi-halberd-corp-ysu-technical-staff-interviewed-in-the-street-reports-podcast/2023-04-19T17:57:22-04:00https://halberdcorporation.com/halberd-corporation-1q23-ceo-letter/2023-04-24T20:53:26-04:00https://halberdcorporation.com/halberd-halb-pursuing-a-nasal-spray-to-counteract-the-effects-of-head-trauma/2023-05-01T20:26:07-04:00https://halberdcorporation.com/halberd-pre-clinical-test-protocol-approved/2023-05-08T18:54:10-04:00https://halberdcorporation.com/halberd-initial-preclinical-testing-phase-at-mississippi-state-university-msu-complete/2023-05-22T20:43:29-04:00https://halberdcorporation.com/halberd-ceo-mid-quarter-update/2023-05-31T05:53:16-04:00https://halberdcorporation.com/halberd-corporation-2q23-ceo-letter/2023-07-19T20:54:59-04:00https://halberdcorporation.com/halberd-mississippi-state-university-msu-testing-of-tbi-nasal-spray-progresses/2023-08-13T19:31:35-04:00https://halberdcorporation.com/halberds-successful-completion-of-sampling-phase-marks-major-milestone-for-project-at-mississippi-state-university-msu/2023-08-21T18:31:47-04:00https://halberdcorporation.com/astounding-early-test-results-of-halberds-traumatic-brain-injury-tbi-project-at-mississippi-state-university-msu/2023-09-06T05:46:15-04:00https://halberdcorporation.com/halberd-and-athena-gtx-collaborate-on-advanced-traumatic-brain-injury-tbi-monitoring-and-applications-for-government-contracts/2023-09-19T19:50:39-04:00https://halberdcorporation.com/halberds-traumatic-brain-injury-tbi-testing-results-replicated-at-mississippi-state-university-msu/2023-10-03T20:16:16-04:00https://halberdcorporation.com/hartman-ceo-and-dr-felder-cto-of-halberd-corp-featured-on-the-street-reports-podcast/2023-10-09T16:58:07-04:00https://halberdcorporation.com/halberd-corporation-plans-to-extend-research-partnership-with-mississippi-state-university/2023-11-14T18:09:30-05:00https://halberdcorporation.com/halberd-corporation-signs-multi-faceted-agreement-with-crodenhealth-com/2023-12-12T18:17:31-05:00https://halberdcorporation.com/halberd-corp-signs-significant-revenue-sharing-agreement-with-athena-gtx/2024-01-10T05:12:05-05:00https://halberdcorporation.com/halberd-corporation-2023-year-end-ceo-update-and-2024-goals/2024-01-10T20:13:22-05:00https://halberdcorporation.com/halberds-top-executives-join-forces-with-athena-gtx-ceo-mark-darrah-unveiling-2024-powerful-partnership-outlook-on-the-street-reports-podcast/2024-02-07T17:33:32-05:00https://halberdcorporation.com/halberd-and-mississippi-state-university-to-commence-stage-ii-advanced-tbi-nasal-spray-testing/2024-02-08T08:07:03-05:00https://halberdcorporation.com/halberds-patented-drug-ldn-the-subject-of-a-limited-clinical-trial-under-an-innovative-four-company-cooperative-research-and-development-crada-contract/2024-04-04T17:47:08-04:00https://halberdcorporation.com/halberds-patented-ldn-drug-has-begun-pre-pilot-trials-with-military-veterans/2024-04-29T18:57:39-04:00https://halberdcorporation.com/halberds-traumatic-brain-injury-treatment-projects-align-with-new-u-s-house-bill/2024-05-08T18:15:45-04:00https://halberdcorporation.com/halberd-athena-gtx-research-promises-a-much-brighter-future/2024-05-21T16:43:28-04:00https://halberdcorporation.com/tbi/2024-07-23T18:32:56-04:00https://halberdcorporation.com/tri-axtm-nasal-spray-technical-progress/2024-08-29T16:41:51-04:00https://halberdcorporation.com/halberd-letter-to-shareholders-patented-ldn-evolves-into-watchdawg-for-veteran-suicide-reduction/2024-09-03T18:06:24-04:00https://halberdcorporation.com/halberd-corp-issues-letter-to-shareholders-patented-ldn-evolves-into-watchdawg-for-veteran-suicide-reduction/2024-09-08T17:19:55-04:00https://halberdcorporation.com/halberd-partnership-secures-contract-from-defense-atomics-corporation-to-address-brain-injury-and-ptsd/2024-09-10T19:05:30-04:00https://halberdcorporation.com/halberd-athena-gtx-report-initial-success-of-watchdawg-ptsd-treatment-pilot-study/2024-11-28T06:29:43-05:00https://halberdcorporation.com/halberd-update-on-watchdawg-ptsd-treatment/2024-12-01T19:39:01-05:00https://halberdcorporation.com/progress-update-on-halberd-athena-gtx-and-athena-telemedicine-partnership-llc-joint-projects/2025-03-16T21:52:55-04:00https://halberdcorporation.com/halberd-athena-gtx-inc-athena-telemedicine-partnership-llc-clinical-study-updates/2025-05-27T21:22:22-04:00https://halberdcorporation.com/halberd-corporation-acquires-neurosense-ai-corp-a-revolutionary-behavioral-intelligence-platform-to-transform-tbi-other-research-and-clinical-assessment/2025-09-28T20:11:12-04:00https://halberdcorporation.com/halberd-corporation-successfully-demonstrates-its-proprietary-breakthrough-ai-technology-for-behavioral-analysis-platform/2025-10-25T17:19:11-04:00https://halberdcorporation.com/halberd-corporation-continues-seeking-government-contracts-with-scientists-at-mississippi-state-university/2026-05-28T11:34:25-04:00https://halberdcorporation.com/halberd-neurosenseai-reach-new-vocal-data-engineering-milestone/2026-05-28T11:34:59-04:00